descriptive case-scenarios for GRADE Approach

Phase-Based Progress Estimates
GRADE Approach+1 More
descriptive case-scenarios - Other
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new way to measure the benefits and harms of medical treatments, to make it easier for doctors and patients to make decisions about what's best.

Eligible Conditions
  • GRADE Approach
  • Decision Support Techniques

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: immediate after completion of study

immediate after completion of study
Large effect of an intervention
Moderate effect of an intervention
Small effect of an intervention

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Alternative threshold estimates
1 of 2
Threshold estimates
1 of 2
Active Control
Experimental Treatment

1406 Total Participants · 2 Treatment Groups

Primary Treatment: descriptive case-scenarios · No Placebo Group · N/A

Threshold estimates
Experimental Group · 1 Intervention: descriptive case-scenarios · Intervention Types: Other
Alternative threshold estimates
ActiveComparator Group · 1 Intervention: descriptive case-scenarios · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: immediate after completion of study

Who is running the clinical trial?

McMaster UniversityLead Sponsor
791 Previous Clinical Trials
1,454,757 Total Patients Enrolled
1 Trials studying GRADE Approach
290 Patients Enrolled for GRADE Approach

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a health research methodologist.
You have a PhD in epidemiology.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 27th, 2021

Last Reviewed: October 14th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.